Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
TLDR
Improving adherence in schizophrenia may have a considerable positive impact on patients and society by focusing on the identified multitude of factors driving nonadherence, including lack of insight, medication beliefs and substance abuse.Abstract:
Background:Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.Methods:We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.Results:Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse,...read more
Citations
More filters
Journal ArticleDOI
Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study
Renato de Filippis,Filippo Antonio Staltari,Matteo Aloi,Elvira Anna Carbone,Marianna Rania,L. DeStefano,Luca Steardo,Cristina Segura-Garcia,Pasquale De Fazio +8 more
TL;DR: In this article , a head-to-head comparison of two different medications (i.e., aripiprazole monohydrate (Ari-LAI) and paliperidone palmitate 1 and 3 months (PP1M, PP3M)) was carried out in a real-world setting, assessing the effectiveness and tolerability of Ari-LAIs and PP1M/PP3M over a 15 month follow-up.
Journal ArticleDOI
Severe Mental Illness Among Adults with Atopic Eczema or Psoriasis: Population-Based Matched Cohort Studies within UK Primary Care
Elizabeth Adesanya,Alasdair D Henderson,Julian Matthewman,Ketaki Bhate,Joseph Hayes,Amy Mulick,Rohini Mathur,Catherine H. Smith,Helena Carreira,Sujit D Rathod,Sinead Langan,Kathryn E. Mansfield +11 more
TL;DR: In this paper , the authors investigated associations between atopic eczema (AE) and severe mental illness (SMI) and incident SMI among adults using matched cohort data from the UK Clinical Practice Research Datalink GOLD.
Journal ArticleDOI
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019
TL;DR: Sedation and nausea were the most common ADRs in children and adolescents, whereas constipation and dizziness were common in adults and the elderly, and serious ADRs were most commonly observed with clozapine.
Journal ArticleDOI
A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia.
Dee Lin,Dominic Pilon,Laura Morrison,Aditi Shah,Marie-Hélène Lafeuille,Patrick Lefebvre,Carmela Benson +6 more
TL;DR: In this article , the authors evaluated and measured out-of-pocket (OOP) costs for antipsychotics among Medicaid beneficiaries with schizophrenia in the MarketScan® Medicaid Database (1 January 2018-31 December 2018).
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: This Explanation and Elaboration document explains the meaning and rationale for each checklist item and includes an example of good reporting and, where possible, references to relevant empirical studies and methodological literature.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more
TL;DR: Recommendations for addressing adherence problems to improve patient outcomes are developed, noting that multiple problems may be involved, requiring a combination of interventions.
Journal ArticleDOI
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
TL;DR: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior.
Related Papers (5)
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more